Different T cell related immunological profiles in COVID-19 patients compared to healthy controls
Copyright © 2021 Elsevier B.V. All rights reserved..
In various pathological conditions, cellular immunity plays an important role in immune responses. Amongimmunecells, T lymphocytes pdomotecellular and humoralresponses as well as innate immunity. Therefore, careful investigation of these cells has a significant impact on accurate knowledge in COVID-19diseasepathogenesis. In current research, the frequency and function of various T lymphocytes involved in immune responses examined in SARS-CoV-2 patients with various disease severity compared to normal subjects. In order to make an accurate comparison among patients with various disease severity, this study was performed on asymptomatic recovered cases (n = 20), ICU hospitalized patients (n = 30), non-ICU hospitalized patients (n = 30), and normal subjects (n = 20). To precisely evaluate T cells activity following purification, their cytokine secretion activity was examined. Similarly, immediately after purification of Treg cells, their inhibitory activity on T cells was investigated. The results showed that COVID-19 patients with severe disease (ICU hospitalized patients) not only had a remarkable increase in Th1 and Th17 but also a considerable decrease in Th2 and Treg cells. More importantly, as the IL-17 and IFN-γ secretion was sharply increased in severe disease, the secretion of IL-10 and IL-4 was decreased. Furthermore, the inhibitory activity of Treg cells was reduced in severe disease patients in comparison to other groups. In severe COVID-19 disease, current findings indicate when the inflammatory arm of cellular immunity is significantly increased, a considerable reduction in anti-inflammatory and regulatory arm occurred.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:97 |
|---|---|
| Enthalten in: |
International immunopharmacology - 97(2021) vom: 15. Aug., Seite 107828 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahmoud Salehi Khesht, Armin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.08.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2021.107828 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326393528 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326393528 | ||
| 003 | DE-627 | ||
| 005 | 20231225194510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2021.107828 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326393528 | ||
| 035 | |a (NLM)34091116 | ||
| 035 | |a (PII)S1567-5769(21)00464-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mahmoud Salehi Khesht, Armin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Different T cell related immunological profiles in COVID-19 patients compared to healthy controls |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a In various pathological conditions, cellular immunity plays an important role in immune responses. Amongimmunecells, T lymphocytes pdomotecellular and humoralresponses as well as innate immunity. Therefore, careful investigation of these cells has a significant impact on accurate knowledge in COVID-19diseasepathogenesis. In current research, the frequency and function of various T lymphocytes involved in immune responses examined in SARS-CoV-2 patients with various disease severity compared to normal subjects. In order to make an accurate comparison among patients with various disease severity, this study was performed on asymptomatic recovered cases (n = 20), ICU hospitalized patients (n = 30), non-ICU hospitalized patients (n = 30), and normal subjects (n = 20). To precisely evaluate T cells activity following purification, their cytokine secretion activity was examined. Similarly, immediately after purification of Treg cells, their inhibitory activity on T cells was investigated. The results showed that COVID-19 patients with severe disease (ICU hospitalized patients) not only had a remarkable increase in Th1 and Th17 but also a considerable decrease in Th2 and Treg cells. More importantly, as the IL-17 and IFN-γ secretion was sharply increased in severe disease, the secretion of IL-10 and IL-4 was decreased. Furthermore, the inhibitory activity of Treg cells was reduced in severe disease patients in comparison to other groups. In severe COVID-19 disease, current findings indicate when the inflammatory arm of cellular immunity is significantly increased, a considerable reduction in anti-inflammatory and regulatory arm occurred | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cell mediated immunity | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a T cells | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a IFNG protein, human |2 NLM | |
| 650 | 7 | |a IL10 protein, human |2 NLM | |
| 650 | 7 | |a IL4 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-17 |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 700 | 1 | |a Karpisheh, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Qubais Saeed, Balsam |e verfasserin |4 aut | |
| 700 | 1 | |a Olegovna Zekiy, Angelina |e verfasserin |4 aut | |
| 700 | 1 | |a Yapanto, Lis M |e verfasserin |4 aut | |
| 700 | 1 | |a Nabi Afjadi, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Aksoun, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Nasr Esfahani, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakhani, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Movahed, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Navneet |e verfasserin |4 aut | |
| 700 | 1 | |a Abbaszadeh-Goudarzi, Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Hallaj, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Dolati, Sanam |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoodpoor, Ata |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi, Vida |e verfasserin |4 aut | |
| 700 | 1 | |a Jadidi-Niaragh, Farhad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 97(2021) vom: 15. Aug., Seite 107828 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:97 |g year:2021 |g day:15 |g month:08 |g pages:107828 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2021.107828 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 97 |j 2021 |b 15 |c 08 |h 107828 | ||